Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Metotrexato en la osteoartritis inflamatoria erosiva de la mano (MERINO)

30 de octubre de 2026 actualizado por: Ida Kristin Haugen, Diakonhjemmet Hospital

El ensayo de metotrexato en la osteoartritis inflamatoria erosiva (MERINO): un ensayo aleatorizado controlado con placebo para investigar la eficacia clínica y la seguridad del metotrexato en la osteoartritis inflamatoria erosiva de la mano.

A placebo-controlled randomized controlled trial exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis.

Participants will be randomized 1:1 to either:

  1. Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if higher doses are not tolerated.
  2. Placebo (control group).

Both arms will receive folic acid 1mg daily.

The treatment duration for both groups is 52 weeks.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

163

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Oslo, Noruega
        • Diakonhjemmet Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain relief from, inability to tolerate or contra-indications to oral paracetamol and/or NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6 weeks before randomization.
  • Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1 distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on ultrasound.

Exclusion Criteria:

A full list of the exclusion criteria for this study comprised the following:

  • Contraindications to methotrexate:

    • Abnormal renal function, defined as serum creatinine >142 µmol/L in women and >168 µmol/L in men, or a glomeruli filtration rate (GFR) <40 mL/min/1.73 m2.
    • Abnormal liver function, defined as transaminases above the upper normal limit, active or previous hepatitis B or C infection, or known cirrhosis
    • Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia).
    • Planned pregnancy within 18 months after screening (men/women), and pregnancy, breastfeeding, or insufficient anti-conception therapy for female fertile participants. Contraception should be maintained during treatment and until the end of systemic exposure, i.e. 3 months after methotrexate discontinuation. Sufficient anti-conception therapy consists of intra-uterine device (coil) or hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections).
    • Alcohol or other drug abuse in the last year.
    • Intolerance to lactose.
  • Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor or anti-CCP antibodies.

  • Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood dyscrasias, and coagulation disorders, history of malignancy (except successfully treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary disease, severe and/or opportunistic infections and/or chronic infections, active tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone marrow hypoplasia, or demyelinating diseases of the central nervous system.

  • Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, injury in finger joints previous 6 months, or palmar tenosynovitis/trigger finger.

  • Oral or intra-muscular steroids in the previous month

  • Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion

  • Analgesics or NSAIDs, unless stable dosage for ≥1 month.

  • Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and require stable dose throughout the study.

  • Disease-modifying osteoarthritis drugs (DMOADs) previous three months.

  • Scheduled hand surgery during study participation.

  • Planning to start other treatments for hand OA in the study participation period.

  • Not able to adhere to the study visit schedule and protocol requirements.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Methotrexate

Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.

Additional Folic acid 1mg prescribed daily.

Methotrexate 2.5mg oral tablet.

Folic acid

Comparador de placebos: Placebo

3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.

Additional Folic acid 1mg prescribed daily.

Placebo capsule

Folic acid

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Finger pain on a visual analogue scale
Periodo de tiempo: 6 months

Difference in self-reported finger joint pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.

6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Finger pain on a visual analogue scale
Periodo de tiempo: Month 1, 3, 9 and 12.

Self-reported finger pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 9 and 12.
Thumb pain on a visual analogue scale
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Self-reported thumb pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Pain most painful finger joint on a visual analogue scale
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Pain most painful finger joint last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Patient-reported disease activity on a visual analogue scale
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Patient-reported disease activity last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Pain all joints on a visual analogue scale
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Pain all joints last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Hand diagram pain
Periodo de tiempo: Month 6.

Finger pain and thumb base pain (yes/no) on hand diagram

Month 6.
Body diagram pain
Periodo de tiempo: Month 6.

Pain in other joints (yes/no) on body diagram

Month 6.
AUSCAN
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Australian/Canadian hand index (AUSCAN), sum score 0-60, higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
OMERACT-OARSI responder criteria
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Fulfillment of Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria.

Month 1, 3, 6, 9 and 12.
EQ-5D
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Quality-adjusted life years (QALYs) based on the health-related utility scores measured by the generic instrument EuroQol 5 dimensions (EQ-5D), sum score 5-35, higher value indicate worse outcome, in addition to a 0-100 visual analogue scale where higher value indicate better outcome.

Month 1, 3, 6, 9 and 12.
MHOQ
Periodo de tiempo: Month 6.

Michigan Hand Outcomes Questionnaire (MHOQ) pain and physical function subscales; function subscale range 10-50, higher value indicate worse outcome; task subscale range 17-85, higher value indicate worse outcome; work subscale range 5-25, higher value indicate worse outcome; pain subscale range 10-48, higher value indicate better outcome.

Month 6.
Grip strength
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Grip strength (in kg; using a hand dynamometer)

Month 1, 3, 6, 9 and 12.
HOOS-12
Periodo de tiempo: Month 6.

Hip disability and Osteoarthritis Outcome Score (HOOS)-12, range 12-60, higher value indicate worse outcome.

Month 6.
KOOS-12
Periodo de tiempo: Month 6.

Knee injury and Osteoarthritis Outcome Score (KOOS)-12, range 12-60, higher value indicate worse outcome.

Month 6.
Concomitant medication
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Concomitant medication

Month 1, 3, 6, 9 and 12.
Tender and swollen joints
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Number of tender and swollen joints (range 0-30), higher values indicate more affected joints.

Month 1, 3, 6, 9 and 12.
Physician-reported disease activity on a visual analogue scale
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Patient-reported disease activity on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Hand radiographs: Kellgren Lawrence
Periodo de tiempo: Month 6 and 12

Conventional radiographs: change in radiographic severity according to Kellgren-Lawrence scale, range 0-4 in each joint higher value indicate worse outcome.

Month 6 and 12
Hand radiographs: Verbruggen-Veys anatomical phase scoring system
Periodo de tiempo: Month 6 and 12

Conventional radiographs: radiographic severity in finger joints according to Verbruggen-Veys anatomical phase scoring system, range 1-5; higher value indicate worse outcome.

Month 6 and 12
Hand radiographs: OARSI atlas
Periodo de tiempo: Month 6 and 12

Conventional radiographs: rdiographic severity according to the Osteoarthritis Research Society International (OARSI) atlas for the presence/severity of osteophytes, joint space narrowing and erosions.

Month 6 and 12
Hand MRI
Periodo de tiempo: Month 6

MRI of dominant hand: number of joints with synovitis and BMLs

Month 6
Hand ultrasound
Periodo de tiempo: Month 1, 3, 6, 9 and 12.

Ultrasound: number of finger joints with synovial thickening and power Doppler signals.

Month 1, 3, 6, 9 and 12.
Knee ultrasound
Periodo de tiempo: Month 6

Ultrasound: degree of synovitis in knee joints

Month 6
Hip ultrasound
Periodo de tiempo: Month 6

Ultrasound: degree of synovitis in hip joints

Month 6
Adverse events
Periodo de tiempo: Through study completion, maximum 12 months, in addition to 3 months after end of treatment.

Number of adverse events, serious adverse events, and withdrawals because of adverse events.

Through study completion, maximum 12 months, in addition to 3 months after end of treatment.

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Sub-study: biopsy of knee OA
Periodo de tiempo: Month 6

Change in synovial cellular composition and gene expression with single-cell RNA sequencing analyses; subgroup analyses, n=16 patients

Month 6
Sub-study: knee pain on a visual analogue scale
Periodo de tiempo: Month 6

Self-reported knee pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.

Month 6
Question about blinding
Periodo de tiempo: Month 12

The participants are asked which treatment they think they have received

Month 12
HADS
Periodo de tiempo: Month 6

Hospital Anxiety and Depression Scales (HADS), range 0-42, higher value indicate worse outcome.

Month 6
PCS
Periodo de tiempo: Month 6

Pain catastrophizing scale, range 0-12, higher value indicate worse outcome.

Month 6
PSQ
Periodo de tiempo: Month 6

Pain Sensitivity Questionnaire (PSQ), range 0-170, higher value indicate worse outcome.

Month 6
Anchor questions for MCII and PASS
Periodo de tiempo: Month 6

Questions about perceived improvement and acceptable symptom state that will be used to define minimally clinically important improvement and patient acceptable symptom state for other questionnaires

Month 6
ASES
Periodo de tiempo: Month 6

Arthritis Self Efficacy Scale (ASES), range 10-100, higher value indicate better outcome.

Month 6
Pain sensitization
Periodo de tiempo: Month 6

Pain sensitization: Pressure Pain Thresholds (PPT) by digital algometer; temporal summation by punctate probes; Conditioned Pain Modulation (CPM) by blood pressure ischemic test.

Month 6
Soluble biomarkers of extracellular matrix turnover
Periodo de tiempo: Month 6 and 12

Markers of collagen degradation (s-COMP, s-C1M, s-C2M, s-C3M, s-CTX1, sHA), collagen synthesis (s-proC2), aggrecan degradation (s-huARGS) and inflammation (s-calprotectin, s- vimentin, s-hsCRP and s-CRPM); Inflammatory cytokines (IL-1β, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, IL-21, IFN-γ, TNF-α, VEGF, GM-CSF, CCL2, CCL3, CCL4, CXCL10) and hormones (leptin and resistin).

Month 6 and 12
Omics
Periodo de tiempo: Month 6 and 12

Omics analyses of whole blood

Month 6 and 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Silla de estudio: Tore K Kvien, MD, PhD, Professor Em.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

12 de agosto de 2021

Finalización primaria (Actual)

2 de septiembre de 2026

Finalización del estudio (Estimado)

1 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

22 de septiembre de 2020

Primero enviado que cumplió con los criterios de control de calidad

1 de octubre de 2020

Publicado por primera vez (Actual)

8 de octubre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • DIA2020-01

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

The trialists and other study personnel that conceive of the study, and then plan, manage, monitor, analyze and publish it, will have access to IPD. Participants' identification code numbers are de-identified by replacing the original code number with a new random code number. Only the PI and project coordinator have access to this code.

The protocol, SAP, ICF, and CSR will be shared with regulatory agents as required.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .